NCT04557800View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

February 19, 2021

Study Completion Date

February 19, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

DNL151

oral dose(s)

DRUG

Placebo

oral dose(s)

Trial Locations (2)

2333

Centre for Human Drug Research, Leiden

9728

PRA Health Sciences, Van Swietenlaan, Groningen

Sponsors
All Listed Sponsors
lead

Denali Therapeutics Inc.

INDUSTRY